Are patients with stage III non-small cell lung cancer treated with chemoradiotherapy at risk for cardiac events? Results from a retrospective cohort study

Juliette Degens*, D. De Ruysscher, Ruud Houben, Bastiaan Kietselaer, Gerben Bootsma, Lizza Hendriks, Ellen Huijbers, Annemie Schols, Anne-Marie C. Dingemans

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Web of Science)


Objectives Dyspnoea is one of the symptoms frequently encountered after treatment with chemoradiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC). Long-term data on mild to moderately severe cardiac events as underlying cause of dyspnoea in patients with stage III NSCLC are lacking. Therefore, the incidence of new cardiac events, with a common terminology criteria for adverse events (CTCAE) score of >= 2 within 5 years after diagnosis, were analysed. Design Retrospective multicentre cohort study of patients with stage III NSCLC treated with CRT from 2006 to 2013. The medical files of the treated patients were reviewed. Outcome measures The primary endpoint of the study was the incidence of new cardiac events with a CTCAE score of >= 2 within 5 years after diagnosis. Secondary endpoint was to identify risk factors associated with the development of a cardiac event. Results Four hundred and sixty patients were included in the study. Of all patients, 150 (32.6%) developed a new cardiac event. In patients with a known cardiac history (n=138), 44.2% developed an event. The most common cardiac events were arrhythmia (14.6%), heart failure (7.6%) and symptomatic coronary artery disease (6.8%). Pre-existent cardiac comorbidity (HR 1.96; p= 2 (HR 2.71; p

Original languageEnglish
Article number036492
Number of pages7
JournalBMJ Open
Issue number9
Publication statusPublished - 2020


  • adult cardiology
  • chemotherapy
  • thoracic medicine
  • respiratory tract tumours
  • adult oncology

Cite this